2025 - Introduced
Missouri S.B.158/H.B. 804
  • For enrollees with an increased risk of opioid abuse, prohibits health insurers from: (1) denying coverage for non-opioid prescription drugs in favor of opioid drugs; (2) requiring an enrollee try an opioid prescription drug prior to approving the use of a non-opioid prescription drug; or (3) requiring a higher cost-sharing for non-opioid prescription drugs.
State Regulated Commercial Parity
Read Senate BillRead House Bill
2025 - Introduced
Montana H.B. 774
  • Prohibits Medicaid and health insurers from denying coverage of a non-opioid in favor of an opioid and requires that in establishing a drug formulary, the Montana Department of Public Health and Human Services must ensure a non-opioid is not disadvantaged or discouraged as compared to coverage of an opioid.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Introduced
Nebraska L.B. 252
  •  Prohibits Medicaid and commercial health insurers from disadvantaging or discouraging a non-opioid drug with respect to coverage of an opioid drug.
Medicaid Parity
Read Bill
2025 - Passed
Nebraska L.R.219
  • Directs the Nebraska Health and Human Services Committee of the Legislature to create a study to examine non-opioid treatment options in Medicaid.
Pain Study
Read Bill
2025 - Introduced
Nevada S.B. 377
  • Requires health insurers and Medicaid cover at least one alternative to an opioid and prohibits insurers from requiring prior authorization or other restrictive requirements for an alternative to an opioid compared to requirements established for an opioid.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Introduced
New Hampshire H.B.241
  • Requires commercial insurers establish parity for non-opioid treatments and therapies.
State Regulated Commercial Parity
Read Bill
2024 - Introduced
New Jersey A4682
  • Prohibits health insurers, Medicaid and School Employees’ Health Benefits from denying coverage of non-opioid prescription drugs in favor of opioid prescription drugs. Further, formularies are prohibited from disincentivizing the use of non-opioids with respect to coverage or cost-sharing.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2025 - Passed
North Dakota S.B. 2113
  • Creates a study that will examine non-opioid pharmacological treatment options and assess the use of existing opioid settlement funds. Additionally, the study will explore strategies to utilize these funds for the development and implementation of an education and awareness initiative regarding non-opioid pain management options.
Pain Study
Read Bill
2025 - Introduced
Oklahoma H.B.1416
  • Ensures that a non-opioid drug approved by the FDA is not disadvantaged or discouraged with respect to coverage relative to an opioid for the treatment or management of pain on the state preferred drug list.
State Employee Health Plan Parity
Read Bill
2024 - Passed
Oklahoma S.B.1344
  • Requires that the state Medicaid preferred drug list and utilization management not disadvantage a non-opioid pain medication relative to an opioid pain medication.
  • Requires the state government to seek grant opportunities relating to education and services regarding non-opioid medications.
  • Provides that the state may assist in using opioid settlement funds to support education regarding non-opioid alternatives.
Medicaid ParityEducation
Read Bill
2025 - Passed
Oregon H.B. 3211
  • Requires the Oregon Health Authority to develop a non-opioid directive form.
Read Bill
2025 - Introduced
Oregon S.B.598
  • Requires health insurers and Medicaid establish parity for opioids and non-opioid treatments.
Medicaid ParityState Regulated Commercial Parity
Read Bill